Male patients with metastatic melanoma don't live as long as females, and their tumors are more likely to become resistant to commonly used treatments. A new study may help explain why: the androgen receptor.
This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892
No comments:
Post a Comment